aTyr Pharma, Inc. (ATYR) Financial Statements
aTyr Pharma, Inc. (ATYR) reported trailing twelve-month revenue of $190000 (down 19.1% year on year) and net income of -$60.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$54.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ATYRaTyr Pharma, Inc.Follow ATYR — free
—
Price chart with a free account
- Market cap
- 16.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 10.5 | 10.4 | 0.4 | 0.2 | 0.2 | — | |
| Research & development | 14.0 | 17.3 | 42.8 | 42.3 | 54.4 | 60.2 | 47.1 | |
| Operating income | -23.0 | -15.9 | -46.4 | -54.9 | -67.9 | -77.6 | -63.9 | |
| Pre-tax income | -23.8 | -16.2 | -45.3 | -50.4 | -64.0 | -74.1 | -60.8 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -16.2 | -16.2 | -45.3 | -50.4 | -64.0 | -74.1 | -60.8 | |
| Diluted EPS ($) | -7.03 | -1.77 | -1.60 | -0.94 | -0.86 | -0.80 | -0.62 | |
| Diluted shares (mn) | — | — | 28.4 | 53.6 | 74.3 | 93.0 | — |
USD millions · SEC XBRL
aTyr Pharma, Inc. — questions
- What is aTyr Pharma, Inc.'s revenue?
- $190000 over the twelve months to 2026-06-30, down 19.1% year on year, from its 10-Q and 10-K filings.
- What is aTyr Pharma, Inc.'s net income?
- -$60.8M over the twelve months to 2026-06-30.
- What is aTyr Pharma, Inc.'s free cash flow?
- -$54.8M over the twelve months to 2026-06-30.
- What are aTyr Pharma, Inc.'s diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from aTyr Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.